NCT04747821已完成4 期
A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 27,711
- 试验地点
- 2
- 主要终点
- Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study
研究概览
简要总结
This is a stepped-wedge cluster randomized trial to assess effectiveness of Sinovac's Adsorbed COVID-19 (Inactivated) vaccine. Residents in the urban area of a municipality are eligible to participate. The city was divided in clusters and those cluster were grouped to determine the offer of vaccination in four steps. The vaccine will be offered to adults (18 years old and above) according to the location of their homes in a cluster. The vaccine schedule is two doses with four-weeks interval. Baseline samples to determine previous immunity will be collected before vaccination.
Cases of COVID-19 reported in the city will be recorded according to the WHO clinical progression scale. Comparison of periods before and after vaccination and relation to immunization coverage will be considered for the assessment of effectiveness in the clusters and groups of clusters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults 18 years of age or older;
- •Resident in the study area;
- •Show voluntary intention to participate in the study, documented by the informed consent form signed by participant.
排除标准
- •For females: Pregnancy (confirmed by positive beta-hCG test), breastfeeding or intent to engage in sexual relations with reproductive intent without use of birth control methods in the three months following vaccination;
- •Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease, according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- •Diseases with impaired immune system including: neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not controlled according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- •Behavioral, cognitive or psychiatric disease that, in the opinion of the principal investigator or his or her representative physician, affects the participant's ability to understand and cooperate with all study protocol requirements;
- •Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has caused medical, professional or family problems, indicated by clinical history;
- •History of severe allergic reactions or anaphylaxis to the study vaccine or to components thereof;
- •History of asplenia;
- •Participation in another clinical trial with an investigational product in the six months prior to enrollment in the study or planned participation in another clinical trial within the two years following enrollment;
- •Previous participation in a study to evaluate a COVID-19 vaccine or prior exposure to a COVID-19 vaccine;
- •Use of immunosuppressant therapy regimens within the six months prior to enrollment in the study for planned use within the two years following enrollment. Immunosuppressant therapy regimens include: antineoplastic chemotherapy, radiation therapy and immunosuppressants to induce transplant tolerance, among others.
- •Use of immunosuppressive doses of corticosteroids within the three months prior to the enrollment in the study and planned use of immunosuppressive doses of corticoids within the three months following enrollment in the study. Immunosuppressive doses of corticosteroids will be considered the equivalent prednisone 20 mg/day for adults, for longer than one week. Continued use of topical or nasal corticosteroids is not considered an immunosuppressant;
- •Received blood products (transfusions or immunoglobulins) within the three months prior to enrollment in the study, or planned administration of blood products or immunoglobulins within the two years following enrollment in the study;
- •Suspected or confirmed fever within the 72 hours prior to vaccination or axillary temperature greater than 37.8 °C* on the day of vaccination (enrollment may be postponed until participant has gone 72 hours without fever);
- •Possible or confirmed case of COVID-19 on the day of vaccination (vaccination can be postponed until the participant completes 72 hours without symptoms or the diagnosis is ruled out);
- •Received live attenuated virus vaccine or inactivated vaccine within the 28 days or 14 days, respectively, prior to enrollment in the study, or immunization planned within the 28 days after enrollment in the study;
- •History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture
- •Any other condition that, in the opinion of the principal investigator or his/her representative physician, could put the safety/rights of potential participants at risk or prevent them from complying with this protocol.
结局指标
主要结局
Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study
时间窗: Thirteen weeks after the beginning of study vaccination
Number of virologically-confirmed symptomatic COVID-19 six weeks after beginning of study vaccination up to thirteen weeks
次要结局
- Incidence of hospitalization and death due to COVID-19 after two-doses immunization schedule in clusters(One year after the beginning of study vaccination)
- Frequency of severe COVID-19 cases(From first vaccination up to one year after first dose)
- Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to pre-existing SARS-CoV-2 antibodies(One year after the beginning of study vaccination)
- Frequency of adverse events of special interest after immunization(From first vaccination up to one year after first dose)
- Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization status(One year after the beginning of study vaccination)
- Change in average number of reported COVID-19 cases in the study area in comparison to other neighboring cities(One year after the beginning of study vaccination)
- Medically-attended adverse reactions to the study vaccine(One week after each vaccination)
- Adherence to vaccination schedule(Six weeks after the beginning of study vaccination of the corresponding cluster)
- Incidence of COVID-19 cases after two-doses immunization schedule in clusters up to one year of study(One year after the beginning of study vaccination)
- Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization coverage(One year after the beginning of study vaccination)
- Acceptability of the study vaccine(Two weeks after the beginning of study vaccination of the corresponding cluster)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Stepped implementation of Enhanced Recovery After Surgery in major gynaecological surgeryPerioperative careelective abdominal surgery, gynaecological oncologyPerioperatieve zorg, electieve abdominale chirurgie, gynaecologische oncologieNL-OMON22049Maastricht University Medical Center (MUMC+)14
已完成
不适用
Machine-Generated Mortality Estimates and Nudges to Promote Advance Care Planning Discussion Among Cancer PatientsOncologyNCT03984773University of Pennsylvania78
终止
不适用
Improve Child Outcomes Through Caregiving in CambodiaChild DevelopmentNCT05197985RTI International3,500
已完成
不适用
Evaluation of the community case detection tool in Northern and Western UgandaMental health conditionsMental and Behavioural DisordersISRCTN19056780War Child3,323
已完成
不适用
Stepped wedge cluster randomized controlled trial for the reduction of dialysis associated infections in ambulatory dialysis Centers.T82.7Infection and inflammatory reaction due to other cardiac and vascular devices, implants and graftsDRKS00019815Charité Universitätsmedizin Berlin Institut für Hygiene und Umweltmedizin Nationales Referenzzentrum für die Surveillance von nosokomialen Infektionen25,721